SUBSTANCE FOR PREVENTING AND IMPROVING ARTHRITIS

• US 20130316032A1
• Filed: 01/18/2012
• Published: 11/28/2013
• Est. Priority Date: 02/02/2011
• Status: Active Grant

• Current Assignee: Asahi Group Holdings, Ltd.
• Original Assignee: Calpis Company Limited (Asahi Group Holdings, Ltd.)
• Inventors: Itoh, Kikuji, Fujiwara, Shigeru
• Granted Patent: US 9,504,720 B2
• Time in Patent Office: Days
• US Class Current: 424/780
• CPC Class Codes: A23K 10/18 of live microorganisms
• CPC Class Codes: A23L 2/52 Adding ingredients adding preservatives A23L2/44
• CPC Class Codes: A23L 33/135 Bacteria or derivatives thereof, e.g. probiotics
• CPC Class Codes: A61K 2300/00 Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
• CPC Class Codes: A61K 31/198 Alpha-amino acids, e.g. alanine or edetic acid [EDTA] betaine A61K31/205; proline A61K31/401; tryptophan A61K31/405; histidine A61K31/4172; peptides not degraded to individual amino acids A61K38/00
• CPC Class Codes: A61K 31/20 having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
• CPC Class Codes: A61K 31/7008 Compounds having an amino group directly attached to a carbon atom of the saccharide radical, e.g. D-galactosamine, ranimustine
• CPC Class Codes: A61K 31/737 Sulfated polysaccharides, e.g. chondroitin sulfate, dermatan sulfate A61K31/727 takes precedence
• CPC Class Codes: A61K 35/74 Bacteria therapeutic use of a bacterial protein A61K38/00
• CPC Class Codes: A61K 35/744 Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
• CPC Class Codes: A61K 45/06 Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
• CPC Class Codes: A61P 19/02 for joint disorders, e.g. arthritis, arthrosis
• CPC Class Codes: A61P 29/00 Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
• CPC Class Codes: A61P 43/00 Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Abstract

This application provides a substance containing disrupted cells of an anti-inflammatory lactic acid bacterium and having an effect of preventing or improving arthritis in a subject, a composition containing the substance and the preparation method thereof, and a method for enhancing the effect of preventing and improving arthritis with the use of the substance.

Claims

1. A substance having both an effect of preventing or improving arthritis in a subject and the following characteristics (a) and (b):

(a) the substance is obtained by disrupting an anti-inflammatory lactic acid bacterium and contains about 5-100% by mass of disrupted cells relative to the lactic acid bacterial cells before disruption; and

(b) the substance has an effect of decreasing an expression level of IL-6 in a subject.

2. The substance according to claim 1, containing about 20-100% by mass of disrupted cells relative to the lactic acid bacterial cells before disruption.

3. The substance according to claim 1, wherein the average long diameter or surface area of each disrupted cell is 90% or less of that of the lactic acid bacterial cell before disruption.

4. The substance according to claim 1, wherein the substance has an effect of decreasing an expression level of IL-6 in the subject to 50% or less of that of the disrupted cells before use.

5. The substance according to claim 1, wherein the anti-inflammatory lactic acid bacterium is characterized in that the expression level of Adam15, Stat3, or Cd40lg in the spleen tissue of an arthritis animal model satisfies at least one of the following conditions as a result of intake of the anti-inflammatory lactic acid bacterium:

expression of Adam15;

less than 0.7;

expression of Stat3;

1.3 or more; and

expression of Cd40lg;

less than 0.7,

when the original expression level of Adam15, Stat3, or Cd40lg in the spleen tissue of an arthritis animal model as a result of intake of a control non-anti-inflammatory substance is designated as 1.

6. The substance according to claim 1, wherein the disrupted cells have an effect of decreasing the expression level of FGF-basic in the subject compared with that before use of the disrupted cells.

7. The substance according to claim 1, wherein the disrupted cells are obtained by physical disruption, chemical treatment, or enzymatic lysis.

8. The substance according to claim 1, wherein the anti-inflammatory lactic acid bacterium is at least one bacterium belonging to a genus selected from the group consisting of the genera Lactobacillus, Bifidobacterium, Enterococcus, Leuconostoc, Streptococcus, Lactococcus, Pediococcus, and Weissella.

9. The substance according to claim 8, wherein the bacterium belonging to the genus Lactobacillus is at least one bacterium selected from the group consisting of Lactobacillus amylovorus, Lactobacillus gasseri, Lactobacillus casei, Lactobacillus paracasei, Lactobacillus zeae, Lactobacillus rhamnosus, Lactobacillus reuteri, Lactobacillus acidophilus, Lactobacillus crispatus, Lactobacillus gallinarum, Lactobacillus brevis, Lactobacillus fermentum, Lactobacillus plantarum, Lactobacillus delbrueckii subsp. bulgaricus, and Lactobacillus johnsonii.

10. The substance according to claim 8, wherein the bacterium belonging to the genus Bifidobacterium is at least one bacterium selected from the group consisting of Bifidobacterium breve, Bifidobacterium longum, Bifidobacterium pseudolongum, Bifidobacterium animalis, Bifidobacterium adolescentis, Bifidobacterium bifidum, Bifidobacterium lactis, Bifidobacterium catenulatum, Bifidobacterium pseudocatenulatum, and Bifidobacterium magnum.

11. The substance according to claim 8, wherein the bacterium belonging to the genus Enterococcus is at least one bacterium selected from the group consisting of Enterococcus faecalis and Enterococcus faecium.

12. The substance according to claim 8, wherein the bacterium belonging to the genus Streptococcus is at least one bacterium selected from the group consisting of Streptococcus thermophiles, Streptococcus lactis, Streptococcus diacetilactis, and Streptococcus faecalis.

13. The substance according to claim 8, wherein the bacterium belonging to the genus Leuconostoc is at least one bacterium selected from the group consisting of Leuconostoc mesenteroides and Leuconostoc lactis.

14. The substance according to claim 8, wherein the bacterium belonging to the genus Lactococcus is at least one bacterium selected from the group consisting of Lactococcus lactis, Lactococcus plantarum, and Lactococcus raffinolactis.

15. The substance according to claim 8, wherein the bacterium belonging to the genus Pediococcus is at least one bacterium selected from the group consisting of Pediococcus pentosaceus and Pediococcus damnosus.

16. The substance according to claim 8, wherein the bacterium belonging to the genus Weissella is at least one bacterium selected from the group consisting of Weissella cibaria, Weissella confusa, Weissella halotolerans, Weissella hellenica, Weissella kandleri, Weissella kimchii, Weissella koreensis, Weissella minor, Weissella paramesenteroides, Weissella soli, Weissella thailandensis, and Weissella viridescens.

17. The substance according to claim 1, wherein the arthritis is rheumatoid arthritis, knee osteoarthritis, tenosynonitis, periomarthritis, tendinitis, or coxitis.

18. A composition for preventing or improving arthritis, comprising the substance according to any claim 1.

19. The composition according to claim 18, further containing at least one known substance having an anti-inflammatory effect.

20. The composition according to claim 19, wherein the known substance having an anti-inflammatory effect is collagen, glucosamine, chondroitin, fatty acid, amino acid, or a salt thereof, or a combination thereof.

21. The composition according to claim 20, wherein the combination is with glucosamine or a salt thereof and chondroitin or a salt thereof.

22. The composition according to claim 18, wherein the arthritis is rheumatoid arthritis, knee osteoarthritis, tenosynonitis, periomarthritis, tendinitis, or coxitis.

23. A product containing the substance of claim 1 as an active ingredient.

24. The product according to claim 23, which is a food or drink, a feedstuff, or a medicament.

25. A method for producing a product for improving a disease or disorder associated with articular inflammation, comprising incorporating the substance of claim 1 into a food or drink, a feedstuff, or a medicament.

26. A method for enhancing the effect of preventing or improving arthritis, comprising, upon production of a food or drink, a feedstuff, or a medicament for preventing or improving arthritis, incorporating the substance of claim 1 and at least one known substance having an anti-inflammatory effect.

27. The method according to claim 26, wherein the known substance having the anti-inflammatory effect is collagen, glucosamine, chondroitin, a fatty acid, an amino acid, or a salt thereof, or a combination of any thereof.

28. The method according to claim 27, wherein the combination is of glucosamine or a salt thereof, and, chondroitin or a salt thereof.